Pfizer and Lilly's tanezumab largely makes the efficacy cut in second PhIII study, but safety issues continue to blight anti-NGF drug
Stark safety issues in the field of anti-NGF pain drugs have led a number of high profile drugmakers to press pause on development, reduce doses or abandon their efforts altogether. On Tuesday, Lilly and Pfizer’s offering — tanezumab — largely passed muster in terms of efficacy in patients with osteoarthritis (OA) pain in a late-stage study, but was unable to shake off that safety issue — triggering aggressive osteoarthritis in a small percentage of patients.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.